Nkarta (NKTX) Total Current Liabilities (2019 - 2026)
Nkarta's (NKTX) quarterly Total Current Liabilities came in at $18.2 million in Q1 2026, down 2.93% year-on-year from $18.8 million in Q1 2025, and down 18.23% quarter-over-quarter from $22.3 million in Q4 2025.
Nkarta (NKTX) Total Current Liabilities (2019 - 2026) Analysis & Trends
Nkarta's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $18.2 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 2.93% year-over-year to $18.2 million in Q1 2026; TTM through Mar 2026 was $18.2 million, a 2.93% decrease from a year earlier, with the FY2025 full-year figure at $22.3 million, up 17.7% from the prior year.
- Total Current Liabilities slipped to $18.2 million in Q1 2026 per NKTX's latest filing, from $22.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $26.6 million in Q2 2023 and bottomed at $10.8 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $22.0 million (2022), against an average of $20.9 million.
- Across the five-year window, Total Current Liabilities soared 139.63% in 2023 and slipped 21.61% in 2024, its largest moves.
- Year by year, Total Current Liabilities stood at $22.0 million in 2022, then grew by 5.82% to $23.3 million in 2023, then decreased by 18.92% to $18.9 million in 2024, then rose by 17.7% to $22.3 million in 2025, then slipped by 18.23% to $18.2 million in 2026.
- Per Business Quant, the three latest NKTX Total Current Liabilities figures stand at $18.2 million (Q1 2026), $22.3 million (Q4 2025), and $19.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | 18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 22.27 Mn |
| Sep 30, 2025 | 18.99 Mn |
| Jun 30, 2025 | 18.93 Mn |
| Mar 31, 2025 | 18.76 Mn |
| Dec 31, 2024 | 18.92 Mn |
| Sep 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 20.86 Mn |
| Mar 31, 2024 | 22.19 Mn |
| Dec 31, 2023 | 23.33 Mn |
| Sep 30, 2023 | 25.64 Mn |
| Jun 30, 2023 | 26.61 Mn |
| Mar 31, 2023 | 25.98 Mn |
| Dec 31, 2022 | 22.05 Mn |
| Sep 30, 2022 | 26.43 Mn |
| Jun 30, 2022 | 13.18 Mn |
| Mar 31, 2022 | 10.84 Mn |
| Dec 31, 2021 | 12.94 Mn |
| Sep 30, 2021 | 12.05 Mn |
| Jun 30, 2021 | 10.26 Mn |